Mydecine Innovations Group Inc. (MYCO.NE)
Mydecine Innovations Group Inc. operates in the Drug Manufacturers - Specialty & Generic industry of the Healthcare sector, headquartered in Vancouver, BC, CA. The stock last traded at $0.35, up 0.00% on the session, giving a market capitalisation of $21.4M. Its beta of 2.29 implies it has historically moved more than the broad market.
Mydecine Innovations Group Inc. is a biotechnology and life sciences enterprise dedicated to advancing and commercializing therapies for a range of mental health conditions. The company specializes in developing treatments for specific populations, including veterans, emergency medical service providers, frontline workers, and individuals affected by post-traumatic stress disorder. It also operates Mindleap, an online telehealth platform offering mental wellness services and support for psychedelic integration, including aftercare. Furthermore, Mydecine engages in drug discovery, developing nature-derived psychedelic-assisted therapeutics, novel compounds, specific therapy protocols, and unique drug delivery systems. The company also manages a hemp cultivation facility in Pottus, Texas. Strategic collaborations include alliances with Leiden University Medical Center, Royal Ottawa Mental Health Centre, and LeadGen Labs for psychedelic drug development, as well as Applied Pharmaceutical Innovation for drug development and clinical trial programs. Founded in 2013, the company, originally known as NewLeaf Brands Inc., rebranded as Mydecine Innovations Group Inc. in June 2020 and is headquartered in Vancouver, Canada.
Mydecine Innovations Group Inc. is most often compared with the following Healthcare names: